NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Small-molecule inhibitors of tyrosine kinase receptors have been used in the treatment of GISTs, dermatofibrosarcoma protuberans, chronic myelogenous leukemia, and others, demonstrating great therapeutic potential [31].